Related Experiment Video
Updated: Mar 3, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Inhibiting the pathological changes of PASMCs is an effective approach for medicinal plants or secondary metabolites
Qi Liang1, Hanghang Gou1, Yi Zhu2
1School of Pharmacy, School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Abstract:
Pulmonary hypertension (PH) is a progressive cardiovascular disease characterized by increased pulmonary vascular resistance and structural remodeling of pulmonary vessels, leading to poor clinical outcomes and high mortality. pulmonary artery smooth muscle cells (PASMCs) migration, apoptosis and abnormal proliferation are the main pathological features leading to the occurrence of PH. Increasing evidence suggests that inhibition of PASMCs pathological changes contributes to the improvement of PH. However, the current clinical treatment of PH is limited, and medicinal plants or secondary metabolites are gradually recognized as potential treatment options for PH. Therefore, this article focuses on inhibiting the abnormal pathological changes of PASMCs, and analyzes and summarizes the mechanism and process of medicinal plants or secondary metabolites in the treatment of PH by inhibiting the abnormal proliferation of PASMCs, so as to provide a direction for the development of medicinal plants or secondary metabolites for the treatment of PH.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...

